SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities

Human coronaviruses, especially SARS-CoV-2, are emerging pandemic infectious diseases with high morbidity and mortality in certain group of patients. In general, SARS-CoV-2 causes symptoms ranging from the common cold to severe conditions accompanied by lung injury, acute respiratory distress syndro...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Ishita, Rizeq, Balsam, Elkord, Eyad, Vranic, Semir, Al Moustafa, Ala-Eddin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464614/
https://www.ncbi.nlm.nih.gov/pubmed/32764454
http://dx.doi.org/10.3390/cancers12082186
_version_ 1783577403901083648
author Gupta, Ishita
Rizeq, Balsam
Elkord, Eyad
Vranic, Semir
Al Moustafa, Ala-Eddin
author_facet Gupta, Ishita
Rizeq, Balsam
Elkord, Eyad
Vranic, Semir
Al Moustafa, Ala-Eddin
author_sort Gupta, Ishita
collection PubMed
description Human coronaviruses, especially SARS-CoV-2, are emerging pandemic infectious diseases with high morbidity and mortality in certain group of patients. In general, SARS-CoV-2 causes symptoms ranging from the common cold to severe conditions accompanied by lung injury, acute respiratory distress syndrome in addition to other organs’ destruction. The main impact upon SARS-CoV-2 infection is damage to alveolar and acute respiratory failure. Thus, lung cancer patients are identified as a particularly high-risk group for SARS-CoV-2 infection and its complications. On the other hand, it has been reported that SARS-CoV-2 spike (S) protein binds to angiotensin-converting enzyme 2 (ACE-2), that promotes cellular entry of this virus in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2). Today, there are no vaccines and/or effective drugs against the SARS-CoV-2 coronavirus. Thus, manipulation of key entry genes of this virus especially in lung cancer patients could be one of the best approaches to manage SARS-CoV-2 infection in this group of patients. We herein provide a comprehensive and up-to-date overview of the role of ACE-2 and TMPRSS2 genes, as key entry elements as well as therapeutic targets for SARS-CoV-2 infection, which can help to better understand the applications and capacities of various remedial approaches for infected individuals, especially those with lung cancer.
format Online
Article
Text
id pubmed-7464614
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74646142020-09-04 SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities Gupta, Ishita Rizeq, Balsam Elkord, Eyad Vranic, Semir Al Moustafa, Ala-Eddin Cancers (Basel) Review Human coronaviruses, especially SARS-CoV-2, are emerging pandemic infectious diseases with high morbidity and mortality in certain group of patients. In general, SARS-CoV-2 causes symptoms ranging from the common cold to severe conditions accompanied by lung injury, acute respiratory distress syndrome in addition to other organs’ destruction. The main impact upon SARS-CoV-2 infection is damage to alveolar and acute respiratory failure. Thus, lung cancer patients are identified as a particularly high-risk group for SARS-CoV-2 infection and its complications. On the other hand, it has been reported that SARS-CoV-2 spike (S) protein binds to angiotensin-converting enzyme 2 (ACE-2), that promotes cellular entry of this virus in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2). Today, there are no vaccines and/or effective drugs against the SARS-CoV-2 coronavirus. Thus, manipulation of key entry genes of this virus especially in lung cancer patients could be one of the best approaches to manage SARS-CoV-2 infection in this group of patients. We herein provide a comprehensive and up-to-date overview of the role of ACE-2 and TMPRSS2 genes, as key entry elements as well as therapeutic targets for SARS-CoV-2 infection, which can help to better understand the applications and capacities of various remedial approaches for infected individuals, especially those with lung cancer. MDPI 2020-08-05 /pmc/articles/PMC7464614/ /pubmed/32764454 http://dx.doi.org/10.3390/cancers12082186 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gupta, Ishita
Rizeq, Balsam
Elkord, Eyad
Vranic, Semir
Al Moustafa, Ala-Eddin
SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities
title SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities
title_full SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities
title_fullStr SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities
title_full_unstemmed SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities
title_short SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities
title_sort sars-cov-2 infection and lung cancer: potential therapeutic modalities
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464614/
https://www.ncbi.nlm.nih.gov/pubmed/32764454
http://dx.doi.org/10.3390/cancers12082186
work_keys_str_mv AT guptaishita sarscov2infectionandlungcancerpotentialtherapeuticmodalities
AT rizeqbalsam sarscov2infectionandlungcancerpotentialtherapeuticmodalities
AT elkordeyad sarscov2infectionandlungcancerpotentialtherapeuticmodalities
AT vranicsemir sarscov2infectionandlungcancerpotentialtherapeuticmodalities
AT almoustafaalaeddin sarscov2infectionandlungcancerpotentialtherapeuticmodalities